Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03571737 · ClinicalTrials.gov registry record · Phase 3

Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department

A Phase 3 study of Trauma and Acute Pain, sponsored by East Carolina University.

Completed
Registry status
Phase 3
Development phase
23
Enrollment target
1
Study location

NCT03571737 is a Phase 3 study of Trauma and Acute Pain that has completed, run by East Carolina University. The registered enrollment target is 23 participants, below the 307-participant average among 56 other Trauma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03571737, a Phase 3 study of Trauma and Acute Pain, has completed, sponsored by East Carolina University.

COMPLETED
Registry status
Phase 3
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the addition of a lidocaine patch to ibuprofen in the treatment of acute musculoskeletal pains. Half of the participants will get only ibuprofen for their pain, while other half will receive lidocaine patch plus the ibuprofen. After addition of the pain medications, the participants will be followed for their pain scores and return visits.

Interventions

  • DRUG Ibuprofen
  • DRUG Lidocaine Patch 4%

Study Locations (1)

North Carolina

  • Vidant Medical Center - Greenville

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2018-06-23
Est. Completion 2021-01-30
Phase Phase 3

Sponsor

East Carolina University

58 total trials

What the Registry Record Tells You About NCT03571737

The ClinicalTrials.gov registry entry for NCT03571737 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 307-participant average among 56 other Trauma trials with a reported enrollment target (93% lower). The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Trauma appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen is the first listed.

NCT03571737 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03571737 about?

NCT03571737 is a clinical study titled "Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department". This study evaluates the addition of a lidocaine patch to ibuprofen in the treatment of acute musculoskeletal pains. Half of the participants will get only ibuprofen for their pain, while other half will receive lidocaine patch plus the ibuprofen. After addition of the pain medications, the particip...

What is the current status of trial NCT03571737?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2018-06-23. Estimated completion is 2021-01-30.

What conditions does trial NCT03571737 study?

This clinical trial studies the following conditions: Trauma, Acute Pain, Emergencies, Injuries, Sprains and Strains.

What interventions are being tested in trial NCT03571737?

The interventions under investigation include: Ibuprofen (DRUG), Lidocaine Patch 4% (DRUG).

Who is sponsoring clinical trial NCT03571737?

This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03571737 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trauma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.